Perfil das interações medicamentosas com a terapia antirretroviral em pessoas vivendo com HIV em um serviço de referência de Belo Horizonte - 2015-2016

Detalhes bibliográficos
Ano de defesa: 2017
Autor(a) principal: Betânia Maira Pontelo
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Minas Gerais
Brasil
MEDICINA - FACULDADE DE MEDICINA
Programa de Pós-Graduação em Ciências da Saúde - Infectologia e Medicina Tropical
UFMG
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
HIV
Link de acesso: http://hdl.handle.net/1843/47243
Resumo: HIV infection may be considered a chronic condition for people living with HIV (PLWH) with access to antiretrovirals (ARVs) and this has effectively increased survival. In the same token this has also facilitated the emergence of other comorbidities, increasing the risk for drug interactions (DIs) and polypharmacy.The profile of these interactions, as well as their consequences in PLWH are still not completely elucidated. The objectives of this study included the description of the profile of these interactions, their prevalenceand their classification accordingly to the potential for significant or nonsignificant DIs. From June 2015 to July 2016, PLWH, on follow-up in an Infectious Diseases Referral Center in Belo Horizonte, Brazil have been investigated for the presence of DIs. A total of 304 patients were included and the majority (75%) had less than 50 years of age, were male (66.4%) and 37.8% were self-defined as brown skinned. Approximately 24% were on five or more medications and half of them presented with DIs. Patients older than 50 years had a higher frequency of ARV DIs with other drugs when compared to younger patients (p = 0.002). No relationship was found between the number of DIs and the effectiveness of ARV. As expected, the higher the number of non-HIV medications used (OR = 1.129 95%CI 1.004-1.209, p = 0.04) was associated with an increase in DIs. The high prevalence of DIs found and the data collected should be useful to establish measures of quaternary prevention and to increase the medication security for PLWH.